We've received confirmation from the US Patent and Trademark Office (USPTO) that a patent will be issued for our CHM CDH17 CAR-T technology. This patent protects our third-generation CAR-T therapy targeting gastrointestinal cancers until at least 2039. CHM CDH17 is currently in a Phase 1/2 clinical trial at leading US cancer centres, including the Sarah Cannon Research Institute, the University of Pennsylvania, and UChicago Medicine. Preclinical studies published in Nature Cancer have shown its ability to eliminate tumours while sparing healthy tissue. This patent strengthens our intellectual property position as we continue advancing CHM CDH17 through clinical development. Read more: https://lnkd.in/eUrZTk8w #ChimericTherapeutics #CHM #CDH17 #CART #CancerResearch #GastrointestinalCancer #Oncology #ASX #ASXNews #Biotech
